Renaissance Technologies’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Renaissance Technologies’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-213	Closed	-$19K	–	4345
2023 Q1	$19K	Buy	+213	New	+$19.7K	﹤0.01%	3835
2022 Q3	–	Sell	-111	Closed	-$34K	–	4489
2022 Q2	$34K	Buy	+111	New	+$42.8K	﹤0.01%	4060
2021 Q4	–	Sell	-105	Closed	-$176K	–	4289
2021 Q3	$176K	Buy	105 +35	+50%	+$72.3K	﹤0.01%	3231
2021 Q2	$197K	Buy	+70	New	+$345K	﹤0.01%	3248
2020 Q4	–	Sell	-68	Closed	-$822K	–	3787
2020 Q3	$822K	Sell	68 -42	-38%	-$510K	﹤0.01%	2605
2020 Q2	$1.33M	Buy	110 +51	+86%	+$575K	﹤0.01%	2408
2020 Q1	$597K	Buy	59 +48	+436%	+$481K	﹤0.01%	2669
2019 Q4	$121K	Buy	+11	New	+$76.9K	﹤0.01%	3286
2019 Q3	–	Sell	-14	Closed	-$101K	–	3776
2019 Q2	$101K	Buy	14 +4	+40%	+$23.2K	﹤0.01%	3397
2019 Q1	$51K	Buy	+10	New	+$63.8K	﹤0.01%	3356

Other funds holding ATXI

Sabby Management Miami Beach, Florida $9.02M AUM 74.48% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Shikiar Asset Management New York $398M AUM 33.64% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Renaissance Technologies's ATXI Position: Q2 2023 in Review

Renaissance Technologies sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2023, closing a stake of 213 shares — an estimated $19K sold.

Renaissance Technologies first reported a position in ATXI in Q1 2019 and held it in 10 quarters. The position peaked at $1.33M in Q2 2020. 11 funds tracked by Wall St. Rank hold ATXI as of Q2 2023.

Renaissance Technologies reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Renaissance Technologies sold 213 Avenue Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $19K.
Renaissance Technologies first reported a position in Avenue Therapeutics, Inc. Common Stock in Q1 2019 and held it in 10 quarters.
Renaissance Technologies's Avenue Therapeutics, Inc. Common Stock position peaked at $1.33M in Q2 2020.
11 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.